EMA offers endorsement for AI optimization of clinical trials. Two Owkin AI models significantly improve the discrimination accuracy for overall survival in hepatocellular carcinoma and mesothelioma. Owkin to develop on-demand prognostic scores for other indications to further reduce clinical trial failure rates
Read Press ReleaseFarmaKeio Outsourcing is proud to announce the release of its latest innovation, the only patented hormone pellet with triamcinolone developed in an FDA-registered 503B outsourcing facility. The pellet is set to provide a new and revolutionary solution to hormone replacement therapy for men and women.
Read Press ReleaseRevolutionizing Clinical Trials: Site Enablement League Unites Industry Leaders to Accelerate Cures and Optimize Site Experience
Read Press ReleaseApproval gives way to the most comprehensive single menu offered by an AST platform while delivering precise, rapid results in 5.5 hours from isolated colonies.
Read Press ReleaseAll-new Yunuverse cloud community capabilities, now standard on the Yunu platform, make it possible for over 1,000 on-demand specialty-trained radiologists, technologists, and study staff to be invited and instantly participate in any of the 4,000 in-flight imaging clinical trials running on the system today. Cancer centers may now extend the reach of trial programs to satellite sites and imaging centers, improving patient access to sophisticated oncology trials.
Read Press ReleaseAccording to Statista, China has the second largest pharmaceutical market in the world and plant-based medicines are very well accepted, which makes China a potential target market for Gb Sciences.
Read Press ReleaseAmplifyBio builds on the T-cell immunology expertise of its South San Francisco-based team, adding technology platforms and capabilities in single-cell analysis and product assessment in the context of a tumor microenvironment.
Read Press ReleaseNew multiyear collaboration between Florence Healthcare and IQVIA to ensure research sites participating in IQVIA studies have access to best-in-class site enablement technology to streamline operations and power remote connectivity.
Read Press ReleaseNTM-001 is an Investigational, Alcohol-Free, Stable Formulation of Ketorolac in a Pre-Mixed Bag for 24h Continuous Infusion. NTM-001 has the Potential to Deliver Opioid-Level Pain Relief Without Analgesic Gaps and Reduce or Eliminate the Need for Opioids. Phase 3 Efficacy and Safety Study is Comparing NTM-001 vs. Placebo, and Includes a Morphine Arm for Assay Sensitivity in Patients with Moderately Severe Pain After Bunionectomy Surgery. Results Expected Second Half 2023.
Read Press Release